

KÖK HÜCRE TEDAVİSİNDE: GEÇMİŞ, BUGÜN VE GELECEK

Mücahid BESNEK¹

Mehmet CANPOLAT²

GİRİŞ

Kök hücreler, kendini yenileme ve çeşitli vücut hücrelerine farklılaşma yeteneği ile benzersiz özelliklere sahip vücut hücreleri olarak kabul edilmektedir. 21. yüzyılda kök hücre konusu, tıbbi araştırma ve tedavi alanlarında büyük önem kazanmıştır. Kök hücre tedavisi, insan vücudundaki hasarlı hücreleri ve dokuları yenilemek veya bu hücreleri eksojen hücreler vererek yeni, sağlıklı ve tamamen işlevsel hücrelerle değiştirmek için kendi kendini yenileme ve farklılaşma dahil olmak üzere kök hücrelerin benzersiz özelliklerini kullanan yeni bir terapötik yaklaşımdır. Kök hücre teknolojisindeki son gelişmeler, henüz tedavi edilmemiş hastalık ve rahatsızlıklardan muzdarip hastalar için yeni bir kapı açmaktadır. İnsan pluripotent kök hücreleri (iPKH'ler) ve multipotent mezenkimal kök hücreler (MKH'ler) dahil olmak üzere kök hücre bazlı terapi, son zamanlarda rejeneratif tipta önemli bir oyuncu olarak ortaya çıkmıştır.¹⁻⁵

Kök hücre, temel olarak belirli bir mikro ortam altında hedef hücrelerde doğrudan farklılaşma yoluyla terapötik etkisini gösterir ve hasarlı veya eksik hücrelerin rejenerasyon sürecinde rol

alır. Bu arada, eksojen kök hücreler hasarlı bölgeye göç edebilir ve endojen kök hücreleri *in situ* aktive ederek hedef hücrelere farklılaştırabilir ve parakrin sekresyon ile ortama etki edebilir.²

KÖK HÜCRE UYGULAMALARININ TARİHİ

'Kök hücre' terimi ilk kez 1868 yılında ünlü Alman biyolog *Ernst Haeckel* tarafından döllenmiş yumurtanın organizmanın tüm hücrelerini meydana getirme özelliklerini tanımlamak için kullanılmıştır.⁶ Kök hücre tedavisinin tarihsel süreci, 1888'de, kök hücre kavramını iki Alman zoolog *Theodor Heinrich Boveri* ve *Valentin Haęccker* tarafından 'daha özellmiş hücrelere farklılaşabilen embriyodaki farklı hücre popülasyonu' şeklinde tanımlanması ile başlamıştır.⁷⁻⁸ 1902'de kemik iliği araştırmaları üzerinde çalışan histolog *Franz Ernst Christian Neumann* ve *Alexander Alexandrowitsch Maximov* tarafından yürütülen araştırmalar, hematopoez olarak da bilinen bir süreç olan olgun kan hücrelerine yol açan ortak progenitor hücrelerin varlığını göstermiştir.^{3,9,10}

1939'da, aplastik anemi teşhisi konan bir hastada, insan kemik iliği naklinin ilk vaka raporu

¹ Arş. Gör. Dr., Erciyes Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları AD., mbesnek@gmail.com, ORCID iD:0009-0008-6547-0501

² Prof. Dr., Erciyes Üniversitesi, Tıp Fakültesi Çocuk Nöroloji AD., drmehmetcanpolat@gmail.com, ORCID iD::0000-0002-2197-8433

ral yolların restorasyonunu artırmak için umut verici teknikleri temsil eder.^{1,35,60,64,65}

Yakın gelecekte, saf kök hücreler veya genetik olarak tasarlanmış mezenkimal kök hücreler kullanılarak, en azından hastalık nedeniyle bozulan nöral yapıyı eski haline getirmek için daha etkili hücresel terapiler elde edilene kadar, daha fazla çalışma ve klinik denemenin gerçekleştirileceğini umut ediyoruz.⁶⁶

KAYNAKLAR

- Zayed, M. A., Sultan, S., Alsaab, H. O., Yousof, S. M., Alrefaei, G. I., Alsubhi, N. H., Alkarim, S., Al Ghamsi, K. S., Bagabir, S. A., Jana, A., Alghamdi, B. S., Atta, H. M., & Ashraf, G. M. (2022). Stem-Cell-Based Therapy: The Celestial Weapon against Neurological Disorders. *Cells*, 11(21), 3476. <https://doi.org/10.3390/cells11213476>.
- Qu, J., Zhou, L., Zhang, H., Han, D., Luo, Y., Chen, J., Li, L., Zou, Z., He, Z., Zhang, M., & Ye, J. (2022). Efficacy and safety of stem cell therapy in cerebral palsy: A systematic review and meta-analysis. *Frontiers in bioengineering and biotechnology*, 10, 1006845. <https://doi.org/10.3389/fbioe.2022.1006845>.
- Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., Heke, M., & Nguyen, L. T. (2022). Stem cell-based therapy for human diseases. Signal transduction and targeted therapy, 7(1), 272. <https://doi.org/10.1038/s41392-022-01134-4>.
- Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*, 126(4), 663–676. <https://doi.org/10.1016/j.cell.2006.07.024>.
- Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*, 131(5), 861–872. <https://doi.org/10.1016/j.cell.2007.11.019>.
- Haeckel, E. H. P. A. (1872). *Natürliche schöpfungsgeschichte*. Verlag von Georg Keimer.
- Boveri T. Befruchtung.in: Merkel F.S. Bonnet R. Ergebnisse der Anatomie und Entwicklungsgeschichte. Joseph Friedrich Bergmann, Wiesbaden1892: 386-485.
- Haecker, V. (1892). Die Kerntheilungsvorgänge bei der Mesodermund Entodermbildung von Cyclops. *Archiv für mikroskopische Anatomie*, 39(1), 556-581.
- Neumann E. Arch. f. Mikrosk. Anatomie und Entwicklungsgeschichte. 1912; 207: 480-520.
- Maximow, A. (1908). Über embryonale Entwicklung der Blut-und Bindegewebzellen bei den Säugetieren. *Verhandl. der Anat. Gesellsch*, 22.: 65-72.
- Osgood, E. E., Riddle, M. C., & Mathews, T. J. (1939). Aplastic anemia treated with daily transfusions and intravenous marrow; case report. *Annals of Internal Medicine*, 13(2), 357-367.
- MATHE, G., JAMMET, H., PENDIC, B., SCHWARZENBERG, L., DUPLAN, J. F., MAUPIN, B., LATARJET, R., LARRIEU, M. J., KALIC, D., & DJUKIC, Z. (1959). Transfusions et greffes de moelle osseuse homologue chez des humains irradiés à haute dose accidentellement [Transfusions and grafts of homologous bone marrow in humans after accidental high dosage irradiation]. *Revue française d'études cliniques et biologiques*, 4(3), 226–238.
- Mathé, G., Bernard, J., Schwarzenberg, L., Larrieu, M. J., Lalanne, C. M., Dutreix, A., ... & Ceoara, B. (1959). Essai de traitement de sujets atteints de leucémie aigüe en rémission par irradiation totale suivie de transfusion de moelle osseuse homologue. *REVUE FRANCAISE D'ETUDES CLINIQUES ET BIOLOGIQUES*, 4(7), 675-704.
- MATHE, G., AMIEL, J. L., SCHWARZENBERG, L., CATTAN, A., & SCHNEIDER, M. (1963). HAEMATOPOIETIC CHIMERA IN MAN AFTER ALLOGENIC (HOMOLOGOUS) BONE-MARROW TRANSPLANTATION. (CONTROL OF THE SECONDARY SYNDROME. SPECIFIC TOLERANCE DUE TO THE CHIMERISM). *British medical journal*, 2(5373), 1633–1635. <https://doi.org/10.1136/bmj.2.5373.1633>.
- Edwards, R. G., Bavister, B. D., & Steptoe, P. C. (1969). Early stages of fertilization in vitro of human oocytes matured in vitro. *Nature*, 221(5181), 632–635. <https://doi.org/10.1038/221632a0>.
- Bongso, A., Fong, C. Y., Ng, S. C., & Ratnam, S. (1994). Isolation and culture of inner cell mass cells from human blastocysts. *Human reproduction* (Oxford, England), 9(11), 2110–2117. <https://doi.org/10.1093/oxfordjournals.humrep.a138401>.
- Bongso, T. A., Fong, C. Y., Ng, C. Y., & Ratnam, S. S. (1994). Blastocyst transfer in human in vitro fertilization: the use of embryo co-culture. *Cell biology international*, 18(12), 1181–1189. <https://doi.org/10.1006/cbir.1994.1044>.
- Evans, M. J., & Kaufman, M. H. (1981). Establishment in culture of pluripotential cells from mouse embryos. *Nature*, 292(5819), 154–156. <https://doi.org/10.1038/292154a0>.
- THOMAS, E. D., LOCHTE, H. L., Jr, LU, W. C., & FERREBEE, J. W. (1957). Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. *The New England journal of medicine*, 257(11), 491–496. <https://doi.org/10.1056/NEJM195709122571102>.
- Thomas, E. D., Storb, R., Fefer, A., Slichter, S. J., Bryant, J. I., Buckner, C. D., Neiman, P. E., Clift, R. A., Funk, D. D., & Lerner, K. E. (1972). Aplastic anaemia treated by marrow transplantation. *Lancet* (London, England), 1(7745), 284–289. [https://doi.org/10.1016/s0140-6736\(72\)90292-9](https://doi.org/10.1016/s0140-6736(72)90292-9).
- Friedenstein, A. J., Chailakhyan, R. K., & Gerasimov, U. V. (1987). Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. *Cell and tissue kinetics*, 20(3), 263–272. <https://doi.org/10.1111/j.1365-2184.1987.tb01309.x>.

22. Friedenstein, A. J., Chailakhjan, R. K., & Lalykina, K. S. (1970). The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. *Cell and tissue kinetics*, 3(4), 393–403. <https://doi.org/10.1111/j.1365-2184.1970.tb00347.x>.
23. Martin G. R. (1981). Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proceedings of the National Academy of Sciences of the United States of America*, 78(12), 7634–7638. <https://doi.org/10.1073/pnas.78.12.7634>.
24. Morshead, C. M., Reynolds, B. A., Craig, C. G., McBurney, M. W., Staines, W. A., Morassutti, D., Weiss, S., & van der Kooy, D. (1994). Neural stem cells in the adult mammalian forebrain: a relatively quiescent subpopulation of subependymal cells. *Neuron*, 13(5), 1071–1082. [https://doi.org/10.1016/0896-6273\(94\)90046-9](https://doi.org/10.1016/0896-6273(94)90046-9).
25. Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998). Embryonic stem cell lines derived from human blastocysts. *Science (New York, N.Y.)*, 282(5391), 1145–1147. <https://doi.org/10.1126/science.282.5391.1145>.
26. Caplan A. I. (1991). Mesenchymal stem cells. *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*, 9(5), 641–650. <https://doi.org/10.1002/jor.1100090504>.
27. Campbell, K. H., McWhir, J., Ritchie, W. A., & Wilmut, I. (1996). Sheep cloned by nuclear transfer from a cultured cell line. *Nature*, 380(6569), 64–66. <https://doi.org/10.1038/380064a0>.
28. Schulz, T. C., Noggle, S. A., Palmarini, G. M., Weiler, D. A., Lyons, I. G., Pensa, K. A., Meedeniya, A. C., Davidson, B. P., Lambert, N. A., & Condle, B. G. (2004). Differentiation of human embryonic stem cells to dopaminergic neurons in serum-free suspension culture. *Stem cells (Dayton, Ohio)*, 22(7), 1218–1238. <https://doi.org/10.1634/stemcells.2004-0114>.
29. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*, 126(4), 663–676. <https://doi.org/10.1016/j.cell.2006.07.024>.
30. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*, 131(5), 861–872. <https://doi.org/10.1016/j.cell.2007.11.019>.
31. Deyle D. R. (2015). Generation of induced pluripotent stem cells. *Methods in molecular biology* (Clifton, N.J.), 1226, 43–58. https://doi.org/10.1007/978-1-4939-1619-1_5.
32. DİNÇER, F. (1982). ORD. PROF. DR. SÜREYYA TAHSİN AYGÜN'ÜN HAYATI VE BİLİMSEL ÇALIŞMALARı. Ankara Üniversitesi Veteriner Fakültesi Dergisi, 29(01.02), 250-276.
33. K.O. Heede: Prof. S. Aygün'ün insan hücre kültürü tedavisi çalışmaları, önemi üzerine. "Die Human. Zellkultur-Terapie" Lausanne 1977 adlı eserin giriş. S. 7-8.
34. Canpolat M. Pediatrik Nöroloji Hastalarında Kök Hücre Uygulamaları. KUMANDAŞ, S., & CANPOLAT, M. (Eds.). (2022). Temel Pediatrik Nöroloji: Tanı ve Tedavi-1. Cilt. 719-746. Akademisyen Kitabevi.
35. Namiot, E. D., Niemi, J. V. L., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2022). Stem Cells in Clinical Trials on Neurological Disorders: Trends in Stem Cells Origins, Indications, and Status of the Clinical Trials. *International journal of molecular sciences*, 23(19), 11453. <https://doi.org/10.3390/ijms231911453>.
36. Sakowski, S. A., & Chen, K. S. (2022). Stem cell therapy for central nervous system disorders: Metabolic interactions between transplanted cells and local microenvironments. *Neurobiology of disease*, 173, 105842. <https://doi.org/10.1016/j.nbd.2022.105842>.
37. Sun JM, Kurtzberg J. Stem cell therapies in cerebral palsy and autism spectrum disorder. *Dev Med Child Neurol*. 2021 May;63(5):503–510. doi: 10.1111/dmcn.14789. Epub 2021 Jan 4. PMID: 33398874.
38. Nguyen, H., Zarriello, S., Coats, A., Nelson, C., Kingsbury, C., Gorsky, A., Rajani, M., Neal, E. G., & Borlongan, C. V. (2019). Stem cell therapy for neurological disorders: A focus on aging. *Neurobiology of disease*, 126, 85–104. <https://doi.org/10.1016/j.nbd.2018.09.011>.
39. Cartier, N., & Aubourg, P. (2010). Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy. *Brain pathology (Zurich, Switzerland)*, 20(4), 857–862. <https://doi.org/10.1111/j.1750-3639.2010.00394.x>.
40. Sun JM, Kurtzberg J. Cell therapy for diverse central nervous system disorders: inherited metabolic diseases and autism. *Pediatr Res*. 2018 Jan;83(1-2):364–371. doi: 10.1038/pr.2017.254. Epub 2017 Nov 8. PMID: 28985203.
41. Wei, M., Yang, Z., Li, S., & Le, W. (2023). Nanotherapeutic and Stem Cell Therapeutic Strategies in Neurodegenerative Diseases: A Promising Therapeutic Approach. *International journal of nanomedicine*, 18, 611–626. <https://doi.org/10.2147/IJN.S395010>.
42. Markham A. (2017). Cerliponase Alfa: First Global Approval. *Drugs*, 77(11), 1247–1249. <https://doi.org/10.1007/s40265-017-0771-8>.
43. Specchio N, Ferretti A, Trivisano M, Pietrafusa N, Pepi C, Calabrese C, Livadiotti S, Simonetti A, Rossi P, Curatolo P, Vigevano F. Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy. *Drugs*. 2021 Jan;81(1):101–123. doi: 10.1007/s40265-020-01440-7.
44. Tamaki SJ, Jacobs Y, Dohse M, Capela A, Cooper JD, Reitsma M, He D, Tushinski R, Belichenko PV, Salehi A, Mobley W, Gage FH, Huhn S, Tsukamoto AS, Weissman IL, Uchida N. Neuroprotection of host cells by human central nervous system stem cells in a mouse model of infantile neuronal ceroid lipofuscinosis. *Cell Stem Cell*. 2009 Sep 4;5(3):310–9. doi: 10.1016/j.stem.2009.05.022.
45. Specchio, N., Ferretti, A., Trivisano, M., Pietrafusa, N., Pepi, C., Calabrese, C., Livadiotti, S., Simonetti, A., Rossi, P., Curatolo, P., & Vigevano, F. (2021). Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy. *Drugs*, 81(1), 101–123. <https://doi.org/10.1007/s40265-020-01440-7>.
46. Villanova M, Bach JR. Allogeneic mesenchymal stem cell therapy outcomes for three patients with spinal muscular atrophy type 1. *Am J Phys Med Rehabil*. 2015 May;94(5):410–5. doi: 10.1097/PHM.0000000000000309.

47. Corti S, Nizzardo M, Simone C, Falcone M, Nardini M, Ronchi D, Donadoni C, Salani S, Riboldi G, Magri F, Menozzi G, Bonaglia C, Rizzo F, Bresolin N, Comi GP. Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. *Sci Transl Med.* 2012 Dec 19;4(165):165ra162. doi: 10.1126/scitranslmed.3004108.
48. Danisovic, L., Culenova, M., & Csobonyeiova, M. (2018). Induced Pluripotent Stem Cells for Duchenne Muscular Dystrophy Modeling and Therapy. *Cells*, 7(12), 253. <https://doi.org/10.3390/cells7120253>.
49. Alanazi, A., Alassiri, M., Jawdat, D., & Almalik, Y. (2022). Mesenchymal stem cell therapy: A review of clinical trials for multiple sclerosis. *Regenerative therapy*, 21, 201–209. <https://doi.org/10.1016/j.reth.2022.07.003>.
50. Genchi, A., Brambilla, E., Sangalli, F., Radaelli, M., Bacigaluppi, M., Furlan, R., Andolfo, A., Drago, D., Magagnotti, C., Scotti, G. M., Greco, R., Vezzulli, P., Ottoboni, L., Bonopane, M., Capilupo, D., Ruffini, F., Belotti, D., Cabiati, B., Cesana, S., Matera, G., ... Martino, G. (2023). Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study. *Nature medicine*, 29(1), 75–85. <https://doi.org/10.1038/s41591-022-02097-3>.
51. Boffa, G., Signori, A., Massacesi, L., Mariottini, A., Sbragia, E., Cottone, S., Amato, M. P., Gasperini, C., Moliola, L., Meletti, S., Repice, A. M., Brescia Morra, V., Salemi, G., Patti, F., Filippi, M., De Luca, G., Lus, G., Zaffaroni, M., Sola, P., Conte, A., ... Italian BMT-MS Study Group and the Italian MS Register (2023). Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis. *Neurology*, 100(11), e1109–e1122. <https://doi.org/10.1212/WNL.00000000000206750>.
52. Gupta, S., Simic, M., Sagan, S. A., Shepherd, C., Duwecker, J., Sobel, R. A., Dandekar, R., Wu, G. F., Wu, W., Pak, J. E., Hauser, S. L., Lim, W., Wilson, M. R., & Zamvil, S. S. (2023). CAR-T Cell-Mediated B-Cell Depletion in Central Nervous System Autoimmunity. *Neurology(R) neuroimmunology & neuroinflammation*, 10(2), e200080. <https://doi.org/10.1212/NXI.000000000002000080>.
53. Lin, Y. J., Mashouf, L. A., & Lim, M. (2022). CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future. *Frontiers in immunology*, 13, 817296. <https://doi.org/10.3389/fimmu.2022.817296>.
54. Ceglie G, Papetti L, Valeriani M, Merli P. Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives. *Int J Mol Sci.* 2020 Jul 26;21(15):5304. doi: 10.3390/ijms21155304.
55. Schneider-Gold, C., & Gilhus, N. E. (2021). Advances and challenges in the treatment of myasthenia gravis. *Therapeutic advances in neurological disorders*, 14, 17562864211065406. <https://doi.org/10.1177/17562864211065406>.
56. Bryant A, Atkins H, Pringle CE, et al. Myasthenia gravis treated with autologous hematopoietic stem cell transplantation. *JAMA Neurol* 2016; 73: 652–8. DOI: 10.1001/jamaneurol.2016.0113.
57. Zhou, L., Zhu, H., Bai, X., Huang, J., Chen, Y., Wen, J., Li, X., Wu, B., Tan, Y., Tian, M., Ren, J., Li, M., & Yang, Q. (2022). Potential mechanisms and therapeutic targets of mesenchymal stem cell transplantation for ischemic stroke. *Stem cell research & therapy*, 13(1), 195. <https://doi.org/10.1186/s13287-022-02876-2>.
58. Dehghani, L., Hashemi, S. M., Saadatnia, M., Zali, A., Oraee-Yazdani, S., Keshel, S. H., Khojasteh, A., & Soleimani, M. (2021). Correction to: Stem Cell-Derived Exosomes as Treatment for Stroke: a Systematic Review. *Stem cell reviews and reports*, 17(2), 439. <https://doi.org/10.1007/s12015-021-10153-7>.
59. Tsuji, O., Sugai, K., Yamaguchi, R., Tashiro, S., Nagoshi, N., Kohyama, J., Iida, T., Ohkubo, T., Itakura, G., Isoda, M., Shinozaki, M., Fujiyoshi, K., Kanemura, Y., Yamamoto, S., Nakamura, M., & Okano, H. (2019). Concise Review: Laying the Groundwork for a First-In-Human Study of an Induced Pluripotent Stem Cell-Based Intervention for Spinal Cord Injury. *Stem cells (Dayton, Ohio)*, 37(1), 6–13. <https://doi.org/10.1002/stem.2926>.
60. Szymoniuk, M., Litak, J., Sakwa, L., Dryla, A., Zezuliniski, W., Czyzewski, W., Kamieniak, P., & Blicharski, T. (2022). Molecular Mechanisms and Clinical Application of Multipotent Stem Cells for Spinal Cord Injury. *Cells*, 12(1), 120. <https://doi.org/10.3390/cells12010120>.
61. Hogendoorn, S., Duijnvisveld, B. J., van Duinen, S. G., Stoel, B. C., van Dijk, J. G., Fibbe, W. E., & Nelissen, R. G. (2014). Local injection of autologous bone marrow cells to regenerate muscle in patients with traumatic brachial plexus injury: a pilot study. *Bone & joint research*, 3(2), 38–47. <https://doi.org/10.1302/2046-3758.32.2000229>.
62. Chang, B. L., & Chang, K. H. (2022). Stem Cell Therapy in Treating Epilepsy. *Frontiers in neuroscience*, 16, 934507. <https://doi.org/10.3389/fnins.2022.934507>.
63. Alok Sharma, Hemangi Sane, Nandini Gokulchandran, Prerna Badhe, Pooja Kulkarni, Suhasini Pai, Ritu Varghese and Amruta Paranjape (June 14th 2017). Stem Cell Therapy in Pediatric Neurological Disabilities, Physical Disabilities - Therapeutic Implications, Uner Tan, IntechOpen, DOI: 10.5772/67656. Available from: <https://www.intechopen.com/chapters/55171>.
64. Gaojian T, Dingfei Q, Linwei L, Xiaowei W, Zheng Z., Wei L., Tong Z., Benxiang N., Yanning Q., Wei Z., et al. Parthenolide Promotes the Repair of Spinal Cord Injury by Modulating M1/M2 Polarization via the NF-KB and STAT 1/3 Signaling Pathway. *Cell Death Discov.* 2020;6:97. doi: 10.1038/s41420-020-00333-8.
65. Fang H., Yang M., Pan Q., Jin H.L., Li H.F., Wang R.R., Wang Q.Y., Zhang J.P. MicroRNA-22-3p Alleviates Spinal Cord Ischemia/Reperfusion Injury by Modulating M2 Macrophage Polarization via IRF5. *J. Neurochem.* 2021;156:106–120. doi: 10.1111/jnc.15042.
66. Lo Furno, D., Mannino, G., & Giuffrida, R. (2018). Functional role of mesenchymal stem cells in the treatment of chronic neurodegenerative diseases. *Journal of cellular physiology*, 233(5), 3982–3999. <https://doi.org/10.1002/jcp.26192>.